250 related articles for article (PubMed ID: 16174656)
1. Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy.
Monti LD; Setola E; Fragasso G; Camisasca RP; Lucotti P; Galluccio E; Origgi A; Margonato A; Piatti P
Am J Physiol Endocrinol Metab; 2006 Jan; 290(1):E54-E59. PubMed ID: 16174656
[TBL] [Abstract][Full Text] [Related]
2. Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
Fragasso G; Piatti Md PM; Monti L; Palloshi A; Setola E; Puccetti P; Calori G; Lopaschuk GD; Margonato A
Am Heart J; 2003 Nov; 146(5):E18. PubMed ID: 14597947
[TBL] [Abstract][Full Text] [Related]
3. Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease.
Marazzi G; Wajngarten M; Vitale C; Patrizi R; Pelliccia F; Gebara O; Pierri H; Ramires JA; Volterrani M; Fini M; Rosano GM
Int J Cardiol; 2007 Aug; 120(1):79-84. PubMed ID: 17134770
[TBL] [Abstract][Full Text] [Related]
4. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy.
Tuunanen H; Engblom E; Naum A; Någren K; Scheinin M; Hesse B; Juhani Airaksinen KE; Nuutila P; Iozzo P; Ukkonen H; Opie LH; Knuuti J
Circulation; 2008 Sep; 118(12):1250-8. PubMed ID: 18765391
[TBL] [Abstract][Full Text] [Related]
5. Addition of n-3 fatty acids to a 4-hour lipid infusion does not affect insulin sensitivity, insulin secretion, or markers of oxidative stress in subjects with type 2 diabetes mellitus.
Mostad IL; Bjerve KS; Basu S; Sutton P; Frayn KN; Grill V
Metabolism; 2009 Dec; 58(12):1753-61. PubMed ID: 19716144
[TBL] [Abstract][Full Text] [Related]
6. Metabolic therapy for patients with diabetes mellitus and coronary artery disease.
Rosano GM; Vitale C; Fragasso G
Am J Cardiol; 2006 Sep; 98(5A):14J-18J. PubMed ID: 16931201
[TBL] [Abstract][Full Text] [Related]
7. Impaired endothelial function and insulin action in first-degree relatives of patients with type 2 diabetes mellitus.
Sonne MP; Højbjerre L; Alibegovic AA; Vaag A; Stallknecht B; Dela F
Metabolism; 2009 Jan; 58(1):93-101. PubMed ID: 19059536
[TBL] [Abstract][Full Text] [Related]
8. Non-oxidative glucose disposal is reduced in type 2 diabetes, but can be restored by aerobic exercise.
Yokoyama H; Mori K; Emoto M; Araki T; Teramura M; Mochizuki K; Tashiro T; Motozuka K; Inoue Y; Nishizawa Y
Diabetes Obes Metab; 2008 May; 10(5):400-7. PubMed ID: 18410564
[TBL] [Abstract][Full Text] [Related]
9. Nonobese, insulin-deficient Ins2Akita mice develop type 2 diabetes phenotypes including insulin resistance and cardiac remodeling.
Hong EG; Jung DY; Ko HJ; Zhang Z; Ma Z; Jun JY; Kim JH; Sumner AD; Vary TC; Gardner TW; Bronson SK; Kim JK
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1687-96. PubMed ID: 17911348
[TBL] [Abstract][Full Text] [Related]
10. Effects of recombinant human IGF-I/IGF-binding protein-3 complex on glucose and glycerol metabolism in type 1 diabetes.
Saukkonen T; Shojaee-Moradie F; Williams RM; Amin R; Yuen KC; Watts A; Acerini CL; Umpleby AM; Dunger DB
Diabetes; 2006 Aug; 55(8):2365-70. PubMed ID: 16873702
[TBL] [Abstract][Full Text] [Related]
11. Peripheral glucose metabolism in patients with insulin resistance and acanthosis nigricans.
Foss MC; Saad MJ; Paccola GM; Paula FJ; Piccinato CE
Horm Metab Res; 1992 Jan; 24(1):26-30. PubMed ID: 1612555
[TBL] [Abstract][Full Text] [Related]
12. Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects.
Bandyopadhyay GK; Yu JG; Ofrecio J; Olefsky JM
Diabetes; 2006 Aug; 55(8):2277-85. PubMed ID: 16873691
[TBL] [Abstract][Full Text] [Related]
13. Myocardial insulin resistance in patients with syndrome X.
Botker HE; Moller N; Schmitz O; Bagger JP; Nielsen TT
J Clin Invest; 1997 Oct; 100(8):1919-27. PubMed ID: 9329954
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase.
Lopaschuk GD; Barr R; Thomas PD; Dyck JR
Circ Res; 2003 Aug; 93(3):e33-7. PubMed ID: 12869392
[TBL] [Abstract][Full Text] [Related]
15. Effects of trimetazidine on myocardial perfusion and left ventricular systolic function in type 2 diabetic patients with ischemic cardiomyopathy.
Belardinelli R; Cianci G; Gigli M; Mazzanti M; Lacalaprice F
J Cardiovasc Pharmacol; 2008 Jun; 51(6):611-5. PubMed ID: 18574390
[TBL] [Abstract][Full Text] [Related]
16. Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes.
Meyer C; Woerle HJ; Dostou JM; Welle SL; Gerich JE
Am J Physiol Endocrinol Metab; 2004 Dec; 287(6):E1049-56. PubMed ID: 15304374
[TBL] [Abstract][Full Text] [Related]
17. Increased insulin-stimulated endothelin-1 release is a distinct vascular phenotype distinguishing Cushing's disease from metabolic syndrome.
Setola E; Losa M; Lanzi R; Lucotti P; Monti LD; Castrignanò T; Galluccio E; Giovanelli M; Piatti P
Clin Endocrinol (Oxf); 2007 Apr; 66(4):586-92. PubMed ID: 17371479
[TBL] [Abstract][Full Text] [Related]
18. Metformin increases blood flow and forearm glucose uptake in a group of non-obese type 2 diabetes patients.
Magalhães FO; Gouveia LM; Torquato MT; Paccola GM; Piccinato CE; Foss MC
Horm Metab Res; 2006 Aug; 38(8):513-7. PubMed ID: 16941277
[TBL] [Abstract][Full Text] [Related]
19. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study.
Rosano GM; Vitale C; Sposato B; Mercuro G; Fini M
Cardiovasc Diabetol; 2003 Nov; 2():16. PubMed ID: 14641923
[TBL] [Abstract][Full Text] [Related]
20. Early administration of trimetazidine may prevent or ameliorate diabetic cardiomyopathy.
Wenmeng W; Qizhu T
Med Hypotheses; 2011 Feb; 76(2):181-3. PubMed ID: 20932648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
